Chat
Feedback
Settings

Settings

Goto Application

278,747 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 27,875
1.20250223280POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS
US - 10.07.2025
Int.Class C07D 405/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
 Appl.No 19081912 Applicant AVILAR THERAPEUTICS, INC. Inventor Jason Allan Wiles

Extracellular protein degraders and compositions are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selective degradation of the Target Extracellular Protein, for example immunoglobulin in vivo to treat disorders mediated by the extracellular protein.

2.202502233122'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME
US - 10.07.2025
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
 Appl.No 19012259 Applicant Taiho Pharmaceutical Co., Ltd. Inventor Gemma Zuend

The invention relates to methods of synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

3.WO/2025/147660MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION
WO - 10.07.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/US2025/010301 Applicant TRILINK BIOTECHNOLOGIES, LLC Inventor XU, Chunping
Described herein are modified RNA molecules where a 3'-stabilizing region is covalently attached to the RNA, and where the 3'-stabilizing region comprises one or more modified nucleosides. Methods of synthesizing said RNAs are also provided herein.
4.WO/2025/146775METHOD FOR PRODUCING GLUCOSE AND CATALYST FOR SAME
WO - 10.07.2025
Int.Class C07H 3/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
3Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
02Monosaccharides
 Appl.No PCT/JP2024/044839 Applicant SUMITOMO CHEMICAL COMPANY, LIMITED Inventor INOMATA, Katsuya
The present invention provides a method for producing glucose, the method comprising bringing a liquid which contains cellulose and water into contact with a solid acid catalyst. The solid acid catalyst contains elemental carbon, elemental titanium, and silica, and has a sulfo group as a surface functional group. The present invention also provides a solid acid catalyst for glucose production, the solid acid catalyst containing elemental carbon, elemental titanium, and silica, while having a sulfo group as a surface functional group.
5.20250223311MINIMAL SAPONIN ANALOGUES, SYNTHESIS AND USE THEREOF
US - 10.07.2025
Int.Class C07H 15/256
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
20Carbocyclic rings
24Condensed ring systems having three or more rings
256Polyterpene radicals
 Appl.No 19011159 Applicant MEMORIAL SLOAN-KETTERING CANCER CENTER Inventor David Y. GIN

Truncated saponin analogues are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and methods of using the truncated saponin analogues.

6.20250223310SYSTEM AND METHOD TO CONVERT CELLULOSIC MATERIALS INTO SUGAR
US - 10.07.2025
Int.Class C07H 1/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
 Appl.No 18290711 Applicant ALLIANCE BIOENERGY PLUS, INC., DBA BLUE BIOFUELS Inventor Benjamin SLAGER

A system for converting cellulosic feedstock to sugar is provided. The system comprises a biomass hopper configured to accept raw material, a conveying tube with a conveying screw configured to separate and transport the raw material, a product heater proximate the conveying screw tube, a drop chute in communication with the conveying screw, and a crusher assembly configured to receive the raw material and defining a reaction zone, grind raw material under pressure to induce a solid-solid chemical reaction to produce the sugar, wherein the crusher assembly comprises a pair of rollers configured to crush the raw material therebetween.

7.WO/2025/145923RUTIN-L-PROLINE EUTECTIC HYDRATE, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 10.07.2025
Int.Class C07H 17/07
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
06Benzopyran radicals
065Benzopyrans
07Benzopyran-4-ones
 Appl.No PCT/CN2024/141716 Applicant COCRYSTAL HEALTH INDUSTRY (ZHEJIANG) CO., LTD. Inventor MEI, Xuefeng
The present invention relates to a rutin-L-proline eutectic hydrate, a preparation method therefor and a use thereof. In the rutin-L-proline eutectic hydrate of the present invention, the molar ratio of rutin to L-proline to water molecules is 1:1:3, and cell parameters are (I), α=90°, β=110.327°, and γ=90°. The rutin-L-proline eutectic hydrate obtained in the present invention has good dissolution performance and remarkably improved bioavailability, thereby better achieving the medicinal value of rutin.
8.3031706Derivados de isoquercetina para el tratamiento y/o prevención de enfermedades oculares
ES - 10.07.2025
Int.Class A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
 Appl.No 202430014 Applicant Consejo Superior de Investigaciones Científicas (CSIC) Inventor Diaz Corrales Francisco Javier
9.20250221440A METHOD FOR PROVIDING AN AMORPHOUS HMO PRODUCT BY DRYING
US - 10.07.2025
Int.Class A23L 33/00
AHUMAN NECESSITIES
23FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; PREPARATION, TREATMENT OR PRESERVATION THEREOF
LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
 Appl.No 18701863 Applicant DSM IP Assets B.V. Inventor Carsten Ydergaard LARSEN

A method for providing a solid amorphous HMO product, said method including drying an aqueous composition of said HMO. Solid amorphous HMO product is obtained via said method, as well as solid amorphous HMO product per se.

10.202502220163-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF
US - 10.07.2025
Int.Class A61K 31/7032
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7032attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
 Appl.No 19069431 Applicant The United States of America, as represented by the Secretary, Department of Health and Human Serv Inventor Lise H. Pasquet

Disclosed is a compound of the formula (I) or (II):

embedded image

wherein a-f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.

# -